Back

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant

Knabl, L.; Lee, H. K.; Wieser, M.; Mur, A.; Zabernigg, A.; Knabl, L.; Rauch, S.; Bock, M.; Schumacher, J.; Kaiser, N.; Furth, P. A.; Hennighausen, L.

2021-05-14 infectious diseases
10.1101/2021.05.11.21256862 medRxiv
Show abstract

Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination. Protection can manifest as early as 10 days following immunization with full protection two weeks following the second dose, but the course is not well-characterized for variants. Here, we investigated the immune transcriptome of six elderly individuals (average age 82 yr.) from an old peoples home, who contracted B.1.351, with four having received the first dose of BNT162b eight to 11 days prior to the onset of COVID-19 symptoms. The patients were hospitalized and received dexamethasone treatment. Immune transcriptomes were established from PBMCs approximately 10 and 35 days after the onset of COVID-19 symptomology. RNA-seq revealed a more intensive immune response in vaccinated patients as compared to unvaccinated ones. Specifically, transcription factors linked to the JAK/STAT pathway, interferon stimulated genes, and genes associated with innate antiviral immunity and COVID-19-SARS-CoV-2 infection were highly enriched in vaccinated patients. This rendered the transcriptomes of the older vaccinated group significantly different than older unvaccinated individuals infected at the same institution and more similar to the immune response of younger unvaccinated individuals (age range 48-62) following B.1.351 infection. All individuals in this study whether vaccinated or not were hospitalized due to B.1.351 infection and one vaccinated patient died illustrating that although an enhanced immune response was documented infection it was insufficient to protect from disease. This highlights the need for maintaining physical distancing and prevention measures throughout the time course of vaccination in older adults.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Frontiers in Aging
10 papers in training set
Top 0.1%
17.5%
2
Aging Cell
144 papers in training set
Top 0.7%
10.1%
3
Scientific Reports
3102 papers in training set
Top 24%
4.9%
4
iScience
1063 papers in training set
Top 3%
4.3%
5
Frontiers in Immunology
586 papers in training set
Top 2%
4.0%
6
GeroScience
97 papers in training set
Top 0.4%
4.0%
7
Nature Communications
4913 papers in training set
Top 39%
3.6%
8
Journal of Medical Virology
137 papers in training set
Top 1%
2.6%
50% of probability mass above
9
Aging
69 papers in training set
Top 0.9%
2.4%
10
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.4%
11
Cell Reports
1338 papers in training set
Top 20%
2.1%
12
Age and Ageing
27 papers in training set
Top 0.2%
2.1%
13
The Journals of Gerontology: Series A
25 papers in training set
Top 0.5%
1.8%
14
eBioMedicine
130 papers in training set
Top 1%
1.7%
15
Translational Psychiatry
219 papers in training set
Top 3%
1.7%
16
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.3%
17
Emerging Microbes & Infections
74 papers in training set
Top 1%
1.2%
18
Nature Aging
51 papers in training set
Top 1%
1.2%
19
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.2%
20
Journal of Infection
71 papers in training set
Top 2%
1.1%
21
mBio
750 papers in training set
Top 10%
1.0%
22
The Lancet Infectious Diseases
71 papers in training set
Top 2%
1.0%
23
Nature Medicine
117 papers in training set
Top 4%
1.0%
24
Brain, Behavior, and Immunity
105 papers in training set
Top 2%
0.9%
25
Journal of Clinical Immunology
11 papers in training set
Top 0.1%
0.9%
26
Viruses
318 papers in training set
Top 5%
0.8%
27
The Lancet Respiratory Medicine
17 papers in training set
Top 0.2%
0.8%
28
Vaccines
196 papers in training set
Top 3%
0.7%
29
Cell Reports Medicine
140 papers in training set
Top 8%
0.7%
30
The Lancet Healthy Longevity
11 papers in training set
Top 0.2%
0.7%